Ticker
ACRS

Price
18.22
Stock movement up
+0.91 (5.26%)
Company name
Aclaris Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Diagnostics & Research
Market cap
1.21B
Ent value
1.22B
Price/Sales
188.46
Price/Book
6.73
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
22.86%
3 year return
162.27%
5 year return
-6.66%
10 year return
-
Last updated: 2022-08-25

DIVIDENDS

ACRS does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales188.46
Price to Book6.73
EV to Sales190.01

FINANCIALS

Per share

Loading...
Per share data
Current share count66.58M
EPS (TTM)-1.32
FCF per share (TTM)-1.00

Income statement

Loading...
Income statement data
Revenue (TTM)6.44M
Gross profit (TTM)2.93M
Operating income (TTM)-80.10M
Net income (TTM)-80.90M
EPS (TTM)-1.32
EPS (1y forward)-1.45

Margins

Loading...
Margins data
Gross margin (TTM)45.46%
Operating margin (TTM)-1244.38%
Profit margin (TTM)-1256.80%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash36.34M
Net receivables633.00K
Total current assets190.88M
Goodwill0.00
Intangible assets7.03M
Property, plant and equipment0.00
Total assets226.53M
Accounts payable8.12M
Short/Current long term debt716.00K
Total current liabilities16.73M
Total liabilities46.33M
Shareholder's equity180.20M
Net tangible assets173.17M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-60.87M
Capital expenditures (TTM)524.00K
Free cash flow (TTM)-61.40M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-44.89%
Return on Assets-35.71%
Return on Invested Capital-44.72%
Cash Return on Invested Capital-33.94%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open17.53
Daily high18.22
Daily low17.35
Daily Volume382K
All-time high32.99
1y analyst estimate34.80
Beta0.61
EPS (TTM)-1.32
Dividend per share-
Ex-div date-
Next earnings date31 Oct 2022

Downside potential

Loading...
Downside potential data
ACRSS&P500
Current price drop from All-time high-44.77%-12.18%
Highest price drop-97.73%-56.47%
Date of highest drop18 Mar 20209 Mar 2009
Avg drop from high-52.08%-11.38%
Avg time to new high72 days12 days
Max time to new high1351 days1805 days
COMPANY DETAILS
ACRS (Aclaris Therapeutics Inc) company logo
Marketcap
1.21B
Marketcap category
Small-cap
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Employees
72
Investor relations
-
SEC filings
CEO
Neal S. Walker
Country
USA
City
Malvern
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ) shareholders have seen the share price descend 10% over the month. But over...
September 15, 2022
WAYNE, Pa., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...
August 30, 2022
WAYNE, Pa., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...
August 25, 2022
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
August 5, 2022
Aclaris (ACRS) delivered earnings and revenue surprises of 13.89% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
August 3, 2022
•Appointed Douglas Manion, M.D., FRCP (C), as President and COO •Initiated Phase 2a Study Activities for Psoriatic Arthritis WAYNE, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (N...
August 3, 2022
Appoints Douglas Manion, M.D., FRCP (C), as President and COO WAYNE, Pa., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focuse...
August 1, 2022
Does Aclaris Therapeutics (ACRS) have what it takes to be a top stock pick for momentum investors? Let's find out.
July 15, 2022
Here is how Aclaris Therapeutics (ACRS) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.
July 8, 2022
This week's Lab Notes has items on a Chester County company's ongoing pursuit of approval for its lead drug candidate, a Bucks County company exploring its options after generating positive study resu...
July 1, 2022
Next page